MAPK3 and colonic neoplasm: To determine if SC-1 reached the same target in the treated colon tumor lines, changes in abundance of phospho-ERK 1/2 (p-ERK) and total ERK1/2 protein were evaluated by immunoblotting at time points similar to those previously studied (Figure 3A).